Oncotarget · 2016 · 46 citations · 40 references
MedicineGynecologyOncologyApoptosisGynecologic OncologyMolecular OncologyApoptosis In CancerMalignant NeoplasmsOvarian CancerOxidative Stress In CarcinogenesisTumor BiologyTumor Suppressor GenesMalignant Ovarian NeoplasmsOvarian Cancer PathogenesisOvarian CarcinogenesisOxidative Stress InjuryReactive Oxygen Species GenerationReactive Oxygen Species Injury
// Suet-Yan Kwan 1, 2 , Xuanjin Cheng 3 , Yvonne T.M. Tsang 1 , Jong-Sun Choi 1, 4 , Suet-Ying Kwan 1, 2 , Daisy I. Izaguirre 1, 2 , Hoi-Shan Kwan 3 , David M. Gershenson 1 , Kwong-Kwok Wong 1, 2 1 Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 2 Cancer Biology Program, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, USA 3 School of Life Sciences, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong 4 The Center for Anti-cancer Companion Diagnostics, Institutes of Entrepreneurial BioConvergence, Seoul National University, Gwanak-Gu, Seoul, Korea Correspondence to: Kwong-Kwok Wong, email: kkwong@mdanderson.org Keywords: ARID1A, reactive oxygen species, elesclomol, ovarian cancer, drug sensitivity Received: December 04, 2015     Accepted: July 18, 2016     Published: July 29, 2016 ABSTRACT Inactivating mutations in ARID1A are found in a broad spectrum of cancer types, with the highest frequency in gynecologic cancers. However, therapeutic strategies targeting ARID1A -mutant cancer cells remain limited. In this study, we aimed to identify drugs sensitivities in ARID1A -mutant cancer cell lines. By analyzing the Genomics of Drug Sensitivity in Cancer database, we found that ARID1A -mutant cancer cell lines were more sensitive to treatment with the reactive oxygen species (ROS)-inducing agent elesclomol. In a panel of 14 gynecologic cancer cell lines, treatment with elesclomol inhibited growth and induced apoptosis more potently in ARID1A -mutant cells. Knockdown of ARID1A in RMG1 and OVCA432 ovarian cancer cells resulted in increased sensitivity to elesclomol, whereas restoration of ARID1A expression in TOV21G ovarian cancer cells resulted in increased resistance to elesclomol. Furthermore, we found that knockdown of ARID1A expression resulted in increased intracellular ROS levels. In ovarian clear cell carcinoma patient samples, low expression of ARID1A correlated with high expression of 8-hydroxyguanosine, a marker for oxidative stress. In summary, we demonstrate for the first time that loss of ARID1A leads to accumulation of ROS and suggest that elesclomol may be used to target ARID1A -mutant gynecologic cancer cells.
40
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina, Giordano Caponigro, Nicolas Stransky et al. · Nature · 2012 · 8.5K citations
Medicine, Oncology, Pharmacology +15
<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas
Kimberly C. Wiegand, Sohrab P. Shah, Osama M. Al‐Agha et al. · New England Journal of Medicine · 2010 · 1.7K citations · Full text